Guidelines for Rehabilitation in Patients With Cardiovascular Disease (JCS 2012)

,

doi:10.1253/circj.cj-66-0094

Cited by 232 publications

(157 citation statements)

References 289 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Although we could not determine the mechanism, our study has shown that mean and max HR were increased on Day 2 in the control group. Since the standard protocol on cardiac rehabilitation in Japan allows bathing and walking freely in the hospital 6 days after PCI [11], a day-to-day increase in the in-hospital activity may influence their HR on Day 2. After being divided into three time periods, the max HR was increased only during night-time.…”

Section: Discussionmentioning

confidence: 99%

“…Patients were routinely treated with heparin, isosorbide dinitrate, clopidogrel, aspirin, a statin, and an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. All the patients were managed in accordance with Japanese guidelines for rehabilitation in patients with cardiovascular disease [11]. After hemodynamic and general conditions had been stabilized within 7 days of the onset of ACS, all patients gave informed consent to participate in the trial.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Shimabukuro

Tanaka

Sata

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundLittle is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of suppressing glucose fluctuations with miglitol on these variables.MethodsThis prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed throughout the Holter ECG.ResultsAlthough frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When divided 24-h time periods into day-time (0700–1800 h), night-time (1800–0000 h), and bed-time (0000–0700 h), we found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctuations during bed-time, which were attenuated by miglitol treatment.ConclusionsIn T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients. Trial registration Unique Trial Number, UMIN000005874 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006929)Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-017-0571-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Shimabukuro

Tanaka

Sata

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…15,16) Physical therapists are mainly responsible for exercise therapy, which is the core component of CR, and evaluations of physical function are conducted to plan exercise programs. 17) The 6-Minute Walk Test (6MWT) is a Objective: The aim of this study was to investigate which method of evaluating physical function could predict 1-year readmission due to worsening of heart failure (HF) in newly diagnosed HF patients. Methods: One hundred sixteen consecutive patients with HF who underwent cardiac rehabilitation at our hospital between May 2012 and September 2015 were retrospectively enrolled.…”

Section: Introductionmentioning

confidence: 99%

Using Physical Function to Predict Hospital Readmission within 1 Year in Patients with Heart Failure

Teramatsu

Shiraishi

Matsushima

et al. 2019

PRM

View full text Add to dashboard Cite

“…12 Moreover, in patients undergoing hemodialysis, renal rehabilitation (RR) and an RR Of note, CR or RR should be performed in COPD patients according to the current CR guidelines, as there is no evidence that CR or RR should be done differently in the presence of COPD.…”

mentioning

confidence: 99%

Pulmonary Rehabilitation in the Era of Multimorbidity and Multiple Disabilities (MMD)

Kohzuki¹,

Cho²,

Lee³

et al. 2017

Pulm Res Respir Med Open J

View full text Add to dashboard Cite

show abstract

Guidelines for Rehabilitation in Patients With Cardiovascular Disease (JCS 2012)

Cited by 232 publications

References 289 publications

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Using Physical Function to Predict Hospital Readmission within 1 Year in Patients with Heart Failure

Pulmonary Rehabilitation in the Era of Multimorbidity and Multiple Disabilities (MMD)

Contact Info

Product

Resources

About